



PTO/SB/08A/B (09-06)

Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

				<i>Complete If Known</i>
Sheet				1
of				2
				Attorney Docket Number
				ALXN-P01-114

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)	MM-DD-YYYY		
/PV/	AD	US-6,255,245	03-12-2002	Evans et al.	
/PV/	AE	US-20030049683	03-13-2003	Bowdish et al.	
/PV/	AF	US-5,660,825	08-26-1997	Sims et al.	

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code ³ -Number-Kind Code ⁴ (if known)	MM-DD-YYYY		
					T ⁵

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IPFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
/PV/	CE	"Alexion Reports Presentation of Membranous Nephritis Clinical Trials"; [online]; Alexion Pharmaceuticals: News; [Retrieved on 2003-06-17]. Retrieved from the Internet: http://www.alexionpharm.com/news/sub_press.cfm?prid=241&selectyear=2002 .			
	CF	Alexion Pharmaceuticals: Complement Inhibitors; [online]; [Retrieved on 2003-06-17]; Retrieved from the Internet: http://www.alexionpharm.com/techplat/complement.cfm .			
	CG	"Alexion Pharmaceuticals Signs Agreement with Lonza Biologics for Commercial Manufacturing"; [online]; Alexion Pharmaceuticals Inc.; [Retrieved on 2003-06-17]; Retrieved from the Internet: http://www.noonanrusso.com/news/view_newsitem.aspx?ItemID=394 .			
	CH	"Alexion Announces Results of Clinical Trial in Paroxysmal Nocturnal Hemoglobinuria Presented at the American Society of Hematology Annual Meeting"; [online]; Alexion Pharmaceuticals, Inc.; [Retrieved on 2003-06-17]; Retrieved from the Internet: http://www.noonanrusso.com/news/view_newsitem.aspx?ItemID=382 .			
	CI	"Alexion announces presentation of preliminary Results from Phase I Pilot Study of Eculizumab Treatment of Patients with Paroxysmal Nocturnal Hemoglobinuria"; [online]; Alexion Pharmaceuticals: News; [Retrieved on 2003-06-18]. Retrieved from the Internet: http://www.alexionpharmaceuticals.com/news/sub_press.cfm?prid=242&selectyear=2002 .			
	CJ	Araten, et al., "High incidence of thrombosis in African-American and Latin-American patients with paroxysmal nocturnal haemoglobinuria," Thromb Haemost 2005; 93:88-91.			
	CK	Audebert et al., "Cerebral ischemic infarction in paroxysmal nocturnal hemoglobinuria," J. Neurol 2005 252 1379-2565 (2005).			
	CL	Fitch et al., "Pharmacology and biological efficacy of a recombinant, humanized, single-chain antibody C5 complement inhibitor in patients undergoing coronary artery bypass graft surgery with cardiopulmonary bypass," Circulation 100(25):2499-2506 (1999)			
▼	CM	"Genes and Disease"; [online]; Paroxysmal nocturnal hemoglobinuria; [Retrieved on 2003-06-017]. Retrieved from the Internet: http://www.ncbi.nlm.nih.gov/disease/PNH.html			

Examiner Signature	Date Considered
--------------------	-----------------

Substitute for form 1449/PTO				Complete if Known	
				Application Number	10/771,552
				Filing Date	February 3, 2004
				First Named Inventor	Leonard Bell
				Art Unit	1644
				Examiner Name	F. P. Vandervegt
Sheet	2	of	<i>2</i>	Attorney Docket Number	ALXN-P01-114

/PV/	CN	Hall et al., "Primary prophylaxis with warfarin prevents thrombosis in paroxysmal nocturnal hemoglobinuria (PNH)," <i>Blood</i> 2003 102 3587-91.	
	CO	Hill et al., "Improvement in the symptoms of smooth muscle dystonia during eculizumab therapy in paroxysmal nocturnal hemoglobinuria," <i>Haematologica</i> 90(12): Abstract #ECR40	
	CP	Hill et al., "Sustained Control of Hemolysis and Symptoms and Reduced Transfusion Requirements over a Period of 2 Years in Paroxysmal Nocturnal Hemoglobinuria (PNH) with Eculizumab Therapy," <i>Blood</i> , 104:Abstract 2823 (2004) with ASH poster final 2004.ppt. ASH poster final 2004.ppt.	
	CQ	Hill et al., "Sustained response and long-term safety of eculizumab in paroxysmal nocturnal hemoglobinuria," <i>Blood</i> 106 2559-2565 (2005).	
	CR	Hillmen et al., "Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria," <i>N Engl J Med</i> 350 552-559 (2004).	
	CS	Hillmen et al., "The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria," <i>N Engl J Med</i> 355 1233-1243 (2006).	
	CT	Inoue N. et al., "Molecular genetics of paroxysmal nocturnal hemoglobinuria," <i>Int J. Hematol.</i> 2003 Feb;77(2):107-112.	
	CU	Kaplan, M. "Eculizumab (Alexion)" <i>Curr Opin Investig Drugs</i> , 2002 Jul;2(7):1017-23.	
	CV	Kinoshita, "Molecular pathogenesis of Paroxysmal Nocturnal Haemoglobinuria,"	
	CW	MacNeil, J.S., "Eculizumab could be paroxysmal nocturnal hemoglobinuria breakthrough,"; MacNeil, J.S.; [online]; Medscape from WebMD; [Retrieved on 2003-06-17. Retrieved from the Internet: http://www.medscape.com/viewarticle/446336 .	
	CX	Mortazavi et al., "The spectrum of PIG-A gene mutations in aplastic anemia/paroxysmal nocturnal hemoglobinuria (AA/PNH): a high incidence of multiple mutations and evidence of a mutational hot spot," <i>Blood</i> 101 2833-2841 (2003).	
	CY	Moyo et al., "Natural history of paroxysmal nocturnal haemoglobinuria using modern diagnostic assays," <i>British J Haematology</i> 126, 133-138 (2004).	
	CZ	"Paroxysmal nocturnal hemoglobinuria, included; PNH, included phosphatidylinositol glycan, class A, pseudogene 1, included; pigap1, included piga-related processed gene, included [online]. OMIM-Online Mendelian Inheritance in Man; John Hopkins University; [Retrieved on 2003-06-18]. Retrieved from the Internet: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=OMIM&dopt=detailed...	
▼	CA1	Richards et al., "Evolution of GPI-Deficient Clones Predicts Clinical Course in Paroxysmal Nocturnal Haemoglobinuria," <i>Blood</i> , 104:Abstract 172 (2004).	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/F. Pierre VanderVegt/	Date Considered	08/06/2007
--------------------	------------------------	-----------------	------------